Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of KYMBEE™ (deflazacort) Tablets, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age ...

STATEN ISLAND, N.Y. — In the “Big Heart” department, Mike DiLeo, executive chef at Max’s Esca, played host to “Savor the ...

In July, the FDA refused to approve Capricor’s application for Deramiocel for the treatment of cardiomyopathy associated with ...

CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ...

Pillar Biosciences, the leader in Decision Medicinetm, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized its pricing determination for oncoReveal CDx. Following its ...

Cornerstone Community Development, in cooperation with Winterwood, CVS Health® and other community organizations, invites the public and media to a special event celebrating the transformation of one ...

The beauty of the DNA code is that organisms interpret it unambiguously. Each three-letter nucleotide sequence, or codon, in ...

SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations - - SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia - CHARLESTOWN, Mass., Dec.

For more than two decades, researchers at the University of Basel, Switzerland, have been investigating a severe form of ...